How many insider trades does FilingIQ track for KTTA?

FilingIQ tracks 55 Form 4 insider transactions for KTTA (Pasithea Therapeutics Corp.), covering filings from Dec 20, 2021 onwards. 7 of those were filed in the last 90 days.

Are KTTA insiders net buyers or net sellers?

Across the full Form 4 history for KTTA, 14 transactions (25%) were open-market purchases and 1 (2%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does KTTA insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is KTTA in?

Pasithea Therapeutics Corp. (KTTA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $18.04M.

KTTA insider trading

NasdaqCM Healthcare

Pasithea Therapeutics Corp. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

25% / 2%

Market cap

$18.04M

About Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumors; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Company website: www.pasithea.com

KTTA insider activity at a glance

FilingIQ has scored 55 insider transactions for KTTA since Dec 20, 2021. The most recent filing in our index is dated May 1, 2026.

Across the full history, 14 open-market purchases and 1 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on KTTA insider trades is 54.9/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live KTTA trades on FilingIQ Raw filings on SEC EDGAR

Latest KTTA Form 4 filings

Marques Tiago Chief Executive Officer

P Nov 28, 2025

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Top insiders trading KTTA

Marques Tiago

3 trades · score 71.0

Frequently asked

How many insider trades does FilingIQ track for KTTA?: FilingIQ tracks 55 Form 4 insider transactions for KTTA (Pasithea Therapeutics Corp.), covering filings from Dec 20, 2021 onwards. 7 of those were filed in the last 90 days.
Are KTTA insiders net buyers or net sellers?: Across the full Form 4 history for KTTA, 14 transactions (25%) were open-market purchases and 1 (2%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does KTTA insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is KTTA in?: Pasithea Therapeutics Corp. (KTTA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $18.04M.

Methodology & sources

Every KTTA insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.